Oncternal Therapeutics, Inc. announced the receipt of a 'Study May Proceed' letter from the U.S. Food and Drug Administration (FDA), 30 days after submitting its Investigational New Drug (IND) application for a Phase 1/2 dose escalation study of ONCT-808, an autologous chimeric antigen receptor (CAR) T therapy targeting ROR1, in patients with aggressive B cell non-Hodgkin's lymphoma (B NHL), including those who have failed previous CD19 CAR T treatment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.84 USD | +2.55% | +3.33% | -17.57% |
May. 09 | Transcript : Oncternal Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.57% | 26.16M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics Receives IND Clearance for ONCT-808, Its Autologous Car T Product Candidate Targeting Ror1 for the Treatment of Aggressive B Cell Lymphoma